Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.

The New England journal of medicine（2022）

引用 61|浏览11

暂无评分

摘要

Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).

查看译文

关键词

eosinophilic esophagitis,dupilumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要